Zag Bio has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize and tolerate self, halting or preventing autoimmune attacks on the body’s own tissues.
Leadership & Board
Current Number of Employees25
Current LinkedIn Followers2,717
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$80M
Total Amount Raised$80M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$80M
Latest Funding Amount$80M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Zag Bio had 25 employees as of September 14, 2026. The number of employees increased by 0 (0.00%) week-over-week.
25Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Zag Bio had 2,717 followers as of September 14, 2026. The number of followers increased by 6 (0.22%) week-over-week.
2,717Latest Followers Count
6(0.22%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.